Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial

PURPOSE: Lower grade gliomas (LGGs) are malignant brain tumors. Current therapy is associated with short- and long-term toxicity. Progression to higher tumor grade is associated with contrast enhancement on MRI. The majority of LGGs harbor mutations in the genes encoding isocitrate dehydrogenase 1 o...

Descripción completa

Detalles Bibliográficos
Autores principales: Mellinghoff, Ingo K., Penas-Prado, Marta, Peters, Katherine B., Burris, Howard A., Maher, Elizabeth A., Janku, Filip, Cote, Gregory M., de la Fuente, Macarena I., Clarke, Jennifer L., Ellingson, Benjamin M., Chun, Saewon, Young, Robert J., Liu, Hua, Choe, Sung, Lu, Min, Le, Kha, Hassan, Islam, Steelman, Lori, Pandya, Shuchi S., Cloughesy, Timothy F., Wen, Patrick Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8364866/
https://www.ncbi.nlm.nih.gov/pubmed/34078652
http://dx.doi.org/10.1158/1078-0432.CCR-21-0611

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8364866/
https://www.ncbi.nlm.nih.gov/pubmed/34078652
http://dx.doi.org/10.1158/1078-0432.CCR-21-0611

Ejemplares similares